Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
作者信息
Schwab Nicholas, Schneider-Hohendorf Tilman, Pignolet Béatrice, Bucciarelli Florence, Scandella Lise, Ciron Jonathan, Biotti Damien, Lebrun-Frenay Christine, Mathey Guillaume, Clavelou Pierre, Pelletier Jean, Ostkamp Patrick, Meinl Ingrid, Windhagen Susanne, Klotz Luisa, Gross Catharina C, Meuth Sven G, Deisenhammer Florian, Brassat David, Wiendl Heinz
机构信息
From the Department of Neurology with Institute of Translational Neurology (N.S., T.S.-H., P.O., L.K., C.C.G., S.G.M., H.W.), University of Münster, Münster, Germany; CRC-SEP-Neurosciences Department (B.P., F.B., L.S., J.C., D. Biotti, D. Brassat), CHU Toulouse, Toulouse, France; CPTP-INSERM U1043-CNRS U5282-Université Toulouse III (B.P., F.B., L.S., D. Brassat), Toulouse, France; APHM (C.L.-F.), Hôpital de la Timone, Pôle de Neurosciences Cliniques, Marseille, France; CHU of Nice (G.M.), Nice, France; CHU Montpied, Neurology, Clermont-Ferrand, France (P.C.); APHM (J.P.), Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, CRCSEP Marseille, France; Institute of Clinical Neuroimmunology (I.M.), Ludwig-Maximilians University, Munich, Germany; Department of Neurology (S.W.), Clinics Osnabrück, Osnabrück, Germany; and Department of Neurology (F.G.), Innsbruck Medical University, Innsbruck, Austria.
出版信息
Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22.
Zotero 插件